{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T18:50:45Z","timestamp":1758048645714,"version":"3.44.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002975","name":"Dainippon Sumitomo Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002975","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.bbrc.2011.10.084","type":"journal-article","created":{"date-parts":[[2011,10,25]],"date-time":"2011-10-25T17:01:03Z","timestamp":1319562063000},"page":"416-420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Anticancer drug irinotecan inhibits homomeric 5-HT3A and heteromeric 5-HT3AB receptor responses"],"prefix":"10.1016","volume":"415","author":[{"given":"Yukiko","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoichi","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2011.10.084_b0005","first-page":"5944","article-title":"Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors","volume":"47","author":"Kunimoto","year":"1987","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2011.10.084_b0010","first-page":"4187","article-title":"Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11","volume":"51","author":"Kawato","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2011.10.084_b0015","first-page":"1721","article-title":"Nonlinear pharmacokinetics of CPT-11 in rats","volume":"50","author":"Kaneda","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2011.10.084_b0020","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1023\/A:1008270717294","article-title":"Topoisomerase I inhibitors: review and update","volume":"8","author":"Rothenberg","year":"1997","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbrc.2011.10.084_b0180","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.26188","article-title":"Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy","author":"Reardon","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.bbrc.2011.10.084_b0030","first-page":"427","article-title":"Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks","volume":"54","author":"Rowinsky","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2011.10.084_b0035","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1248\/yakushi.124.491","article-title":"Serotonin and anticancer drug-induced emesis","volume":"124","author":"Minami","year":"2004","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.bbrc.2011.10.084_b0040","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S1734-1140(09)70132-X","article-title":"Overview on 5-HT receptors and their role in physiology and pathology of the central nervous system","volume":"61","author":"Filip","year":"2009","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.bbrc.2011.10.084_b0045","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1074\/jbc.M208814200","article-title":"A novel class of ligand-gated ion channel is activated by Zn2+","volume":"278","author":"Davies","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2011.10.084_b0050","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0378-1119(03)00503-1","article-title":"Cloning, physical mapping and expression analysis of the human 5-HT3 serotonin receptor-like genes HTR3C, HTR3D and HTR3E","volume":"310","author":"Niesler","year":"2003","journal-title":"Gene"},{"key":"10.1016\/j.bbrc.2011.10.084_b0055","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/16941","article-title":"The 5-HT3B subunit is a major determinant of serotonin-receptor function","volume":"397","author":"Davies","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2011.10.084_b0060","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2165\/00019053-200018060-00002","article-title":"Stratified administration of serotonin 5-HT3 receptor antagonists (setrons) for chemotherapy-induced emesis. Economic implications","volume":"18","author":"Sanchez","year":"2000","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.bbrc.2011.10.084_b0065","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1126\/science.1718042","article-title":"Primary structure and functional expression of the 5HT3 receptor, a serotonin-gated ion channel","volume":"254","author":"Maricq","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2011.10.084_b0070","doi-asserted-by":"crossref","first-page":"7057","DOI":"10.1093\/nar\/12.18.7057","article-title":"Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs","volume":"12","author":"Krieg","year":"1984","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbrc.2011.10.084_b0075","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0028-3908(03)00032-7","article-title":"The GABA(A) receptor antagonist picrotoxin inhibits 5-hydroxytryptamine type 3A receptors","volume":"44","author":"Das","year":"2003","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbrc.2011.10.084_b0080","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1124\/jpet.105.085076","article-title":"Modulation of human 5-hydroxytryptamine type 3AB receptors by volatile anesthetics and n-alcohols","volume":"314","author":"Stevens","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbrc.2011.10.084_b0085","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.molbrainres.2005.09.011","article-title":"Co-expression of the 5-HT(3B) subunit with the 5-HT(3A) receptor reduces alcohol sensitivity","volume":"142","author":"Hayrapetyan","year":"2005","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.bbrc.2011.10.084_b0090","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/1040-8428(96)00201-6","article-title":"Irinotecan (CPT-11): pharmacology and clinical applications","volume":"24","author":"Masuda","year":"1996","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bbrc.2011.10.084_b0095","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ctrv.2006.07.001","article-title":"Irinotecan in the treatment of colorectal cancer","volume":"32","author":"Fuchs","year":"2006","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bbrc.2011.10.084_b0100","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0304-3835(97)00428-X","article-title":"Oral versus intraperitoneal administration of irinotecan in the treatment of human neuroblastoma in nude mice","volume":"124","author":"Choi","year":"1998","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbrc.2011.10.084_b0105","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1349-7006.1993.tb02031.x","article-title":"Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11","volume":"84","author":"Araki","year":"1993","journal-title":"Jpn. J. Cancer Res."},{"key":"10.1016\/j.bbrc.2011.10.084_b0110","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1200\/JCO.1995.13.1.210","article-title":"Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients","volume":"13","author":"Abigerges","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2011.10.084_b0115","first-page":"4347","article-title":"Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients","volume":"54","author":"de Forni","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2011.10.084_b0120","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1200\/JCO.1996.14.10.2688","article-title":"Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer","volume":"14","author":"Canal","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2011.10.084_b0125","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1080\/02841860701666089","article-title":"Irinotecan-induced central nervous system toxicity. Report on two cases and review of the literature","volume":"47","author":"Hamberg","year":"2008","journal-title":"Acta Oncol."},{"key":"10.1016\/j.bbrc.2011.10.084_b0130","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/ajcn\/57.4.486","article-title":"Food preferences, body weight, and platelet-poor plasma serotonin and catecholamines","volume":"57","author":"Blum","year":"1993","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.bbrc.2011.10.084_b0135","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/0024-3205(88)90543-7","article-title":"Serotonergic status in human blood","volume":"43","author":"Ortiz","year":"1988","journal-title":"Life Sci."},{"key":"10.1016\/j.bbrc.2011.10.084_b0140","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/bjc.1992.242","article-title":"Changes in serotonin metabolism in cancer patients: its relationship to nausea and vomiting induced by chemotherapeutic drugs","volume":"66","author":"Cubeddu","year":"1992","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbrc.2011.10.084_b0145","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1200\/JCO.1995.13.3.681","article-title":"Plasma chromogranin A: a marker of serotonin release and of emesis associated with cisplatin chemotherapy","volume":"13","author":"Cubeddu","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2011.10.084_b0150","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0304-3940(94)11170-N","article-title":"Detection of 5-HT3R-A, a 5-HT3 receptor subunit, in submucosal and myenteric ganglia of rat small intestine using in situ hybridization","volume":"184","author":"Johnson","year":"1995","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bbrc.2011.10.084_b0155","doi-asserted-by":"crossref","first-page":"6732","DOI":"10.1523\/JNEUROSCI.22-15-06732.2002","article-title":"Differential composition of 5-hydroxytryptamine3 receptors synthesized in the rat CNS and peripheral nervous system","volume":"22","author":"Morales","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbrc.2011.10.084_b0160","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ejca.2010.11.030","article-title":"Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug\u2013drug interaction study","volume":"47","author":"van der Bol","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbrc.2011.10.084_b0165","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/BF00169258","article-title":"Modulation by 5-HT3 and 5-HT4 receptors of the release of 5-hydroxytryptamine from the guinea-pig small intestine","volume":"347","author":"Gebauer","year":"1993","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.bbrc.2011.10.084_b0170","first-page":"131","article-title":"Chemical modulation of 5-HT3 and 5-HT4 receptors affects the release of 5-hydroxytryptamine from the ferret and rat intestine","volume":"89","author":"Minami","year":"1995","journal-title":"Res. Commun. Mol. Pathol. Pharmacol."},{"key":"10.1016\/j.bbrc.2011.10.084_b0175","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1200\/JCO.2003.05.164","article-title":"Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients","volume":"21","author":"Tremblay","year":"2003","journal-title":"J. Clin. Oncol."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X11018961?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X11018961?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T10:57:07Z","timestamp":1757761027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X11018961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0006291X11018961"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2011.10.084","relation":{},"ISSN":["0006-291X"],"issn-type":[{"type":"print","value":"0006-291X"}],"subject":[],"published":{"date-parts":[[2011,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticancer drug irinotecan inhibits homomeric 5-HT3A and heteromeric 5-HT3AB receptor responses","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2011.10.084","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}